143 related articles for article (PubMed ID: 11152093)
1. Biomarkers for the detection of bladder cancer.
Ross JS; Cohen MB
Adv Anat Pathol; 2001 Jan; 8(1):37-45. PubMed ID: 11152093
[TBL] [Abstract][Full Text] [Related]
2. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.
Eissa S; Kassim S; El-Ahmady O
Curr Opin Obstet Gynecol; 2003 Oct; 15(5):395-403. PubMed ID: 14501243
[TBL] [Abstract][Full Text] [Related]
3. Detecting recurrent bladder cancer: new methods and biomarkers.
Ross JS; Cohen MB
Expert Rev Mol Diagn; 2001 May; 1(1):39-52. PubMed ID: 11901799
[TBL] [Abstract][Full Text] [Related]
4. Ancillary methods for the detection of recurrent urothelial neoplasia.
Ross JS; Cohen MB
Cancer; 2000 Apr; 90(2):75-86. PubMed ID: 10794156
[No Abstract] [Full Text] [Related]
5. Comparison of screening methods in the detection of bladder cancer.
Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer biomarkers: current developments and future implementation.
Alvarez A; Lokeshwar VB
Curr Opin Urol; 2007 Sep; 17(5):341-6. PubMed ID: 17762628
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in the diagnosis of primary bladder cancer. A systematic review.
Glas AS; Roos D; Deutekom M; Zwinderman AH; Bossuyt PM; Kurth KH
J Urol; 2003 Jun; 169(6):1975-82. PubMed ID: 12771702
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer.
Landman J; Chang Y; Kavaler E; Droller MJ; Liu BC
Urology; 1998 Sep; 52(3):398-402. PubMed ID: 9730450
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
10. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
11. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Lokeshwar VB; Soloway MS
J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
[TBL] [Abstract][Full Text] [Related]
12. [The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology].
Oeda T; Manabe D
Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):1-5. PubMed ID: 11235137
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers in the detection of recurrent transitional cell carcinoma of the bladder: a brief review.
Zaher A; Sheridan T
Acta Cytol; 2001; 45(4):575-81. PubMed ID: 11480721
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study.
Sullivan PS; Nooraie F; Sanchez H; Hirschowitz S; Levin M; Rao PN; Rao J
Cancer; 2009 Jun; 117(3):167-73. PubMed ID: 19365828
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
[TBL] [Abstract][Full Text] [Related]
16. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of recurrent bladder cancer using the Bard BTA stat Test.
Sarosdy MF; Hudson MA; Ellis WJ; Soloway MS; deVere White R; Sheinfeld J; Jarowenko MV; Schellhammer PF; Schervish EW; Patel JV; Chodak GW; Lamm DL; Johnson RD; Henderson M; Adams G; Blumenstein BA; Thoelke KR; Pfalzgraf RD; Murchison HA; Brunelle SL
Urology; 1997 Sep; 50(3):349-53. PubMed ID: 9301696
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
20. Urinary markers of bladder carcinoma.
Dey P
Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
